Indivior (INDV) Releases Full-Year 2026 Financial Guidance and Key Business Updates
Published on January 08, 2026
Indivior PLC (Nasdaq: INDV), a company specializing in medications for opioid use disorder, has announced its financial guidance for the full year 2026. The firm anticipates total net revenue ranging from $1,125 million to $1,195 million, with SUBLOCADE® net revenue expected between $905 million and $945 million. Non-GAAP operating expenses are projected to be between $430 million and $450 million, while adjusted EBITDA is estimated to fall between $535 million and $575 million.
Strategic Progress and Leadership Insights
CEO Joe Ciaffoni expressed that 2025 served as a pivotal year for Indivior, stating, “We established the Indivior Action Agenda and completed Phase I – Generate Momentum by growing U.S. SUBLOCADE net revenue, simplifying the organization, and transforming our operating model.” He noted that the company is well-positioned to pursue its next phase, Phase II – Accelerate, which aims to advance SUBLOCADE’s dispense unit growth and overall net revenue growth throughout 2026.
CFO Ryan Preblick added that the company expects an 11% growth in SUBLOCADE net revenue at the midpoint of their guidance range, along with a 35% increase in adjusted EBITDA and a 14 percentage point improvement in adjusted EBITDA margin in 2026.
Recent Business Developments
- Completion of Phase I of the Indivior Action Agenda – Generate Momentum, leading to annual non-GAAP operating expense savings of at least $150 million.
- Transition into Phase II – Accelerate, focusing on enhanced dispense unit growth and net revenue for SUBLOCADE throughout 2026.
- Inclusion in the S&P SmallCap 600® index effective December 22, 2025.
- Approval to change its domicile from the U.K. to the U.S., establishing a new parent company, Indivior Pharmaceuticals, Inc., expected to take effect on January 26, 2026.
- Resolution of the legacy U.S. Department of Justice matter with a full payment of $295 million.
Financial Outlook for 2026
Indivior's financial guidance for 2026 includes:
- Total Net Revenue: $1,125 million to $1,195 million
- Total SUBLOCADE Net Revenue: $905 million to $945 million
- Non-GAAP Operating Expenses: $430 million to $450 million
- Adjusted EBITDA: $535 million to $575 million
About Indivior
Indivior Pharmaceuticals is dedicated to improving the lives of patients by developing effective treatments for opioid use disorder (OUD). Their goal is to ensure that all patients have access to evidence-based therapy for OUD, aspiring to transform this public health crisis into a recognized, manageable chronic disease.
For more information, visit www.indivior.com or connect with Indivior on LinkedIn at www.linkedin.com/company/Indivior.
Important Financial Notes
The announcement includes financial metrics not defined by US GAAP, such as non-GAAP operating expenses and adjusted EBITDA. These measures should not be considered superior to GAAP results. Variations of these financial measures may not align with similar metrics used by other companies.
For more clarity on financial expectations, Indivior emphasizes that factors influencing future performances may include sales fluctuations, competitive impacts, and potential unanticipated costs.